Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial
Research output: Contribution to journal › Journal article › Research › peer-review
In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk of stroke. We therefore aimed to assess the efficacy and safety of apixaban compared with warfarin in prespecified subgroups of patients with and without previous stroke or TIA.
| Original language | English |
|---|---|
| Journal | The Lancet Neurology |
| Volume | 11 |
| Issue number | 6 |
| Pages (from-to) | 503-11 |
| Number of pages | 9 |
| ISSN | 1474-4422 |
| DOIs | |
| Publication status | Published - Jun 2012 |
ID: 48592372